CD44-positive Cancer Stem-like Cells as a Potential Source of Peritoneal Metastasis After Surgery

Background/Aim: The role of CD44 in gastric cancer-derived peritoneal metastasis is currently unknown. It was previously shown that viable, tumorigenic cancer cells are spilled into the peritoneal cavity during surgery, providing a potential cause of peritoneal recurrence after surgery. The purpose of this study was to elucidate the mechanism of peritoneal metastasis of gastric cancer through the expression of CD44 and to propose a method for preventing peritoneal recurrence. Materials and Methods: Gastric cancer cell line MKN-45 was sorted into CD44+ and CD44− cells and then injected intraperitoneally into NOD/ShiJic-scidJcl mice. Differences in tumor-initiating capacity between the two groups were assessed using in vivo limiting dilution assays. Tumors harvested from both groups were examined for CD44 and ALDH1A1 expression using immunohistochemistry. The effects of CD44 blockade with anti-CD44 antibody on cell invasion and peritoneal metastasis formation in vivo were assessed. Results: CD44+ cells showed significantly higher efficiency in initiating peritoneal tumor than CD44− cells. Blockade of CD44 significantly reduced peritoneal dissemination of CD44+ cells in vivo, indicating that the CD44 function of intraperitoneally disseminated cancer cells helped promote the formation of peritoneal metastasis. The margin of established tumors showed clusters of cells co-expressing CD44 and ALDH1A1. Peritoneally administered CD44− cells resulted in peritoneal metastases consisting of CD44+ and CD44− cancer cells. Conclusion: CD44 expressing cells are a potential source of peritoneal metastasis after surgery and could be a promising target for preventing peritoneal recurrence.

[1]  M. Tani,et al.  Long-term prognosis of patients with cancer-related genes detected in postoperative peritoneal washings obtained during curative gastrectomy. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  Xing Liu,et al.  Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use , 2021, Journal of cellular and molecular medicine.

[3]  T. Yevsa,et al.  Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies , 2020, Frontiers in Immunology.

[4]  X. Mo,et al.  Peritoneal Metastatic Cancer Stem Cells of Gastric Cancer with Partial Mesenchymal-Epithelial Transition and Enhanced Invasiveness in an Intraperitoneal Transplantation Model , 2020, Gastroenterology research and practice.

[5]  H. Clevers,et al.  Defining Adult Stem Cell Function at Its Simplest: The Ability to Replace Lost Cells through Mitosis. , 2019, Cell stem cell.

[6]  D. Welch,et al.  Defining the Hallmarks of Metastasis. , 2019, Cancer research.

[7]  A. Kajdacsy-Balla,et al.  CD44 Regulates Formation of Spheroids and Controls Organ-Specific Metastatic Colonization in Epithelial Ovarian Carcinoma , 2019, Molecular Cancer Research.

[8]  Y. Kodera,et al.  Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[10]  A. Berghold,et al.  Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients. , 2017, Anticancer research.

[11]  Antonina V. Kurtova,et al.  A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer , 2017, Nature.

[12]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[13]  J. Kinoshita,et al.  Establishing a xenograft mouse model of peritoneal dissemination of gastric cancer with organ invasion and fibrosis , 2017, BMC Cancer.

[14]  M. Tani,et al.  Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer , 2016, British Journal of Cancer.

[15]  Camille Stephan-Otto Attolini,et al.  Targeting metastasis-initiating cells through the fatty acid receptor CD36 , 2016, Nature.

[16]  X. Lai,et al.  CD44 and CD44v6 are Correlated with Gastric Cancer Progression and Poor Patient Prognosis: Evidence from 42 Studies , 2016, Cellular Physiology and Biochemistry.

[17]  K. Pavlakis,et al.  The Prognostic Value of CD44 Expression in Epithelial-Mesenchymal Transition: Preliminary Data from Patients with Gastric and Esophageal Cancer. , 2016, In vivo.

[18]  F. Mégraud,et al.  Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma , 2016, Clinical Cancer Research.

[19]  J. Jagirdar,et al.  CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy , 2016, Clinical Cancer Research.

[20]  T. Tani,et al.  Viable Cancer Cells in the Remnant Stomach are a Potential Source of Peritoneal Metastasis after Curative Distal Gastrectomy for Gastric Cancer , 2016, Annals of Surgical Oncology.

[21]  Michael D. Brooks,et al.  Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. , 2015, Cell stem cell.

[22]  A. Ejaz,et al.  Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. , 2014, Journal of the American College of Surgeons.

[23]  M. Biffoni,et al.  CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. , 2014, Cell stem cell.

[24]  T. Tani,et al.  Surgery-Induced Peritoneal Cancer Cells in Patients Who Have Undergone Curative Gastrectomy for Gastric Cancer , 2014, Annals of Surgical Oncology.

[25]  T. Hibi,et al.  CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence , 2013, British Journal of Cancer.

[26]  H. Clevers,et al.  Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties , 2013, Cell.

[27]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[28]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[29]  T. Wang,et al.  Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.

[30]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[31]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[32]  Takuma Sasaki,et al.  Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites , 2007, Cancer science.

[33]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[34]  S. Grinstein,et al.  CD44 is a phagocytic receptor. , 2006, Blood.

[35]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Denis,et al.  Epitope mapping of four novel CD44 monoclonal antibodies using surface plasmon resonance and soluble CD44 , 2001, Transfusion medicine.

[37]  M. Davies,et al.  Induction of hyaluronan metabolism after mechanical injury of human peritoneal mesothelial cells in vitro. , 2000, Kidney international.

[38]  J. Kira,et al.  Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain , 1997, Journal of virology.

[39]  H. Dvorak,et al.  Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. , 1996, The American journal of pathology.

[40]  Q. He,et al.  Monoclonal antibodies to CD44 and their influence on hyaluronan recognition , 1995, The Journal of cell biology.

[41]  M. Davies,et al.  The source and possible significance of hyaluronan in the peritoneal cavity. , 1994, Kidney international.